Title : A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.

Pub. Date : 2008 Mar

PMID : 17505827






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PURPOSE: Sunitinib, an oral multitargeted tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FLT3, KIT, and RET, is currently approved for the treatment of imatinib-refractory GIST and advanced renal cell carcinoma at a dose of 50 mg daily for 4 weeks followed by a 2-week off period (4/2 schedule). Sunitinib kinase insert domain receptor Homo sapiens